ALTASCIENCES
23.3.2021 14:50:09 CET | Business Wire | Press release
WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.
The expansion added 5,000 square feet of configurable clinical trial facilities. This further ensures participants have access to a socially distanced, comfortable space in which to complete study procedures. An additional 700 square feet of lab space was also added. Read the original press release .
“We are thrilled to be able to provide more functional space for our study participants and staff, and create a dosing environment that can support blinded administrations of medications. This expansion increases unit capacity, operational efficiency, and freedom of movement. We look forward to showcasing our brand-new expansion to our clients and for our subjects to have added comfort during their participation at our site ,” said Dr. David Nguyen, Chief Medical and Operations Officer at WCCT Global, an Altasciences company.
Chris Perkin, CEO of Altasciences, adds, “The dosing of the first participants in our West Coast clinic expansion is an important milestone in the evolution of our clinical trial offerings, for both long-term stays and outpatient visits. We are excited to see it come to fruition, and contribute to Altasciences’ continued growth to support early-stage drug development .”
Altasciences acquired WCCT Global on February 12, 2021, adding a third clinical location to existing facilities in Kansas City, U.S.A. and Montreal, Canada. Read the acquisition press release .
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005755/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Announces Partnership with Profound to Expand AI Visibility Across Its Global Brand Portfolio14.9.2026 18:32:00 CEST | Press release
Partnership enables the company to lead prestige beauty's transition to AI-powered discovery while better understanding how consumers discover, evaluate, and engage with its brands across AI answer engines The Estée Lauder Companies Inc. (NYSE: EL) today announced a global strategic partnership with Profound, the category-defining AI marketing platform, advancing its ambition to be prestige beauty’s leader in AI-native discovery. The partnership will provide the company with visibility into how its full portfolio of brands is represented across leading generative AI platforms, as well as opportunities to optimize that representation. This partnership establishes the company as the first in prestige beauty to deploy Profound’s capabilities globally across the company’s full portfolio and operationalize Generative Engine Optimization (GEO) and AI marketing at scale. As consumers increasingly turn to ChatGPT, Gemini, and other AI assistants to discover products, compare recommendations, a
AMAALA Yacht Club Opens, Putting the Red Sea on the Global Yachting Map14.9.2026 18:00:00 CEST | Press release
Luxury sailing, wellness and exploration converge at Saudi Arabia's newest yachting destination Red Sea Global (RSG), the regenerative tourism developer, has announced that AMAALA Yacht Club has officially begun operations, marking a major milestone in establishing the Saudi Red Sea as a new global destination for luxury yachting, sailing and marine tourism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914160771/en/ AMAALA Yacht Club, the new luxury yachting destination on Saudi Arabia’s Red Sea coast. Nestled within AMAALA Marina Village, the AMAALA Yacht Club is now welcoming founding members and visiting yachts to moor and explore the destination. Located approximately 2,000 nautical miles from Monaco, the club provides a new winter destination for the world’s luxury sailing community, which traditionally migrates from the Mediterranean to the Caribbean or Indian Ocean from October. Positioned closer to the Mediterra
Behind the Stage Lights: How Students Learned to Trust Their Voices with Doha Debates14.9.2026 15:40:00 CEST | Press release
During high school years in Model United Nations, Dahlia Al-Ansari learned to argue on behalf of a country she was assigned to represent. But when Doha Debates invited her to join a town hall debate in Toronto this July, she faced an unfamiliar challenge: sharing her own beliefs about a timely issue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914150232/en/ Students from Qatar, Canada and Mexico during their visit to the University of Toronto as part of the Doha Debates Town Hall experience in Canada. (Photo: AETOSWire) An 18-year-old biological sciences student at Carnegie Mellon University in Qatar, Al-Ansari hadn’t traveled to defend a predetermined position. Instead, she discovered that she was there to think critically, express her own viewpoint and remain open to diverse perspectives. This shift required her to navigate uncharted waters, but “I’m happy that it did,” she says. “It’s showing me the importance of sp
Matt Shafer Joins Golub Capital as Head of Golub Equity Continuation Partners14.9.2026 15:30:00 CEST | Press release
Golub Capital (“the Firm”) today announced the appointment of Matt Shafer as Managing Director and Head of the Firm’s GP-led private equity secondaries strategy, Golub Equity Continuation Partners (“GECP”). In this role, he will be responsible for leading the continued growth and development of the strategy and helping expand the Firm’s equity investment capabilities. Matt will work closely with Greg Cashman, Vice Chair and Co-Head of Golub Capital’s Sponsor Finance practice, to expand Golub Capital’s activity in this growing market. Shafer brings nearly three decades of global experience as an investor, financier and advisor working with private equity firms. He was most recently Head of Capital Solutions and U.S. Private Equity at Northleaf Capital Partners. In this role, Shafer helped lead the firm’s private equity investment activities, including secondaries, co‑investments and structured capital. Prior to Northleaf, he was Partner and Head of Americas Private Equity at Vision Capi
HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI14.9.2026 15:19:00 CEST | Press release
Investment positions AMRA to meet growing global demand for precise, scalable advanced muscle and fat imaging in clinical research and healthcare. AMRA Medical today announced an investment from HealthCap, one of Europe’s leading life science venture capital firms. This milestone marks a significant step in AMRA’s growth, underscoring market confidence in the company’s vision to transform the measurement and understanding of muscle and fat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914838191/en/ HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI HealthCap’s backing comes as quantitative MRI gains vital importance in understanding how fat distribution and muscle composition influence disease, treatment response, and patient outcomes. Built on over 15 years of research, AMRA’s proprietary methods move beyond conventional metrics—like weight, and BMI and muscle function tests—to provide th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom